520 related articles for article (PubMed ID: 22699621)
1. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
Pérez-Mancera PA; Rust AG; van der Weyden L; Kristiansen G; Li A; Sarver AL; Silverstein KA; Grützmann R; Aust D; Rümmele P; Knösel T; Herd C; Stemple DL; Kettleborough R; Brosnan JA; Li A; Morgan R; Knight S; Yu J; Stegeman S; Collier LS; ten Hoeve JJ; de Ridder J; Klein AP; Goggins M; Hruban RH; Chang DK; Biankin AV; Grimmond SM; ; Wessels LF; Wood SA; Iacobuzio-Donahue CA; Pilarsky C; Largaespada DA; Adams DJ; Tuveson DA
Nature; 2012 Apr; 486(7402):266-70. PubMed ID: 22699621
[TBL] [Abstract][Full Text] [Related]
2. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.
Pal A; Dziubinski M; Di Magliano MP; Simeone DM; Owens S; Thomas D; Peterson L; Potu H; Talpaz M; Donato NJ
Neoplasia; 2018 Feb; 20(2):152-164. PubMed ID: 29248719
[TBL] [Abstract][Full Text] [Related]
3. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
[TBL] [Abstract][Full Text] [Related]
4. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer.
Liu L; Yao D; Zhang P; Ding W; Zhang X; Zhang C; Gong S; Zhang Y; Wang J; Sun T; Ren Z
Oncol Rep; 2017 Dec; 38(6):3531-3537. PubMed ID: 29130109
[TBL] [Abstract][Full Text] [Related]
6. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
7. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
8. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
9. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
10. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
11. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.
Gopinathan A; Denicola GM; Frese KK; Cook N; Karreth FA; Mayerle J; Lerch MM; Reinheckel T; Tuveson DA
Gut; 2012 Jun; 61(6):877-84. PubMed ID: 22157328
[TBL] [Abstract][Full Text] [Related]
14. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
[TBL] [Abstract][Full Text] [Related]
15. RET, a targetable driver of pancreatic adenocarcinoma.
Amit M; Na'ara S; Fridman E; Vladovski E; Wasserman T; Milman N; Gil Z
Int J Cancer; 2019 Jun; 144(12):3014-3022. PubMed ID: 30515799
[TBL] [Abstract][Full Text] [Related]
16. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
Perurena N; Lock R; Davis RA; Raghavan S; Pilla NF; Ng R; Loi P; Guild CJ; Miller AL; Sicinska E; Cleary JM; Rubinson DA; Wolpin BM; Gray NS; Santagata S; Hahn WC; Morton JP; Sansom OJ; Aguirre AJ; Cichowski K
Cell Rep Med; 2023 Apr; 4(4):101007. PubMed ID: 37030295
[TBL] [Abstract][Full Text] [Related]
17. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
18. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Schwickart M; Huang X; Lill JR; Liu J; Ferrando R; French DM; Maecker H; O'Rourke K; Bazan F; Eastham-Anderson J; Yue P; Dornan D; Huang DC; Dixit VM
Nature; 2010 Jan; 463(7277):103-7. PubMed ID: 20023629
[TBL] [Abstract][Full Text] [Related]
19. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.
von Figura G; Fukuda A; Roy N; Liku ME; Morris Iv JP; Kim GE; Russ HA; Firpo MA; Mulvihill SJ; Dawson DW; Ferrer J; Mueller WF; Busch A; Hertel KJ; Hebrok M
Nat Cell Biol; 2014 Mar; 16(3):255-67. PubMed ID: 24561622
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-specific protease 14 (USP14) promotes proliferation and metastasis in pancreatic ductal adenocarcinoma.
Hang C; Gong C; Fang Y; Chen L; Zhu J
J Mol Histol; 2021 Apr; 52(2):187-196. PubMed ID: 33394290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]